Cargando…

Preoperative chemoradiation with capecitabine, irinotecan and cetuximab in rectal cancer: significance of pre-treatment and post-resection RAS mutations

BACKGROUND: The influence of EGFR pathway mutations on cetuximab-containing rectal cancer preoperative chemoradiation (CRT) is uncertain. METHODS: In a prospective phase II trial (EXCITE), patients with magnetic resonance imaging (MRI)-defined non-metastatic rectal adenocarinoma threatening/involvin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gollins, Simon, West, Nick, Sebag-Montefiore, David, Myint, Arthur Sun, Saunders, Mark, Susnerwala, Shabbir, Quirke, Phil, Essapen, Sharadah, Samuel, Leslie, Sizer, Bruce, Worlding, Jane, Southward, Katie, Hemmings, Gemma, Tinkler-Hundal, Emma, Taylor, Morag, Bottomley, Daniel, Chambers, Philip, Lawrie, Emma, Lopes, Andre, Beare, Sandy
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2017
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5672930/ https://www.ncbi.nlm.nih.gov/pubmed/28859058 http://dx.doi.org/10.1038/bjc.2017.294

Ejemplares similares

Preoperative downstaging chemoradiation with concurrent irinotecan and capecitabine in MRI-defined locally advanced rectal cancer: a phase I trial (NWCOG-2)
por: Gollins, S W, et al.
Publicado: (2009)

Irinotecan+5-fluorouracil with concomitant pre-operative radiotherapy in locally advanced non-resectable rectal cancer: a phase I/II study
por: Iles, S M, et al.
Publicado: (2008)

The impact of co-expression of wild-type EGFR and its ligands determined by immunohistochemistry for response to treatment with cetuximab in patients with metastatic colorectal cancer
por: Khelwatty, Said, et al.
Publicado: (2016)

HER2 Expression Is Predictive of Survival in Cetuximab Treated Patients with RAS Wild Type Metastatic Colorectal Cancer
por: Khelwatty, Said A., et al.
Publicado: (2021)

A prospective phase II study of pre-operative chemotherapy then short-course radiotherapy for high risk rectal cancer: COPERNICUS
por: Gollins, Simon, et al.
Publicado: (2018)

Comparing mutation calls in fixed tumour samples between the affymetrix OncoScan® array and PCR based next-generation sequencing
por: Wood, Henry M., et al.
Publicado: (2017)

Development of phimosis as an adverse drug reaction to capecitabine with irinotecan
por: Patel, Priyeshkumar, et al.
Publicado: (2022)

Cross-laboratory validation of the OncoScan® FFPE Assay, a multiplex tool for whole genome tumour profiling
por: Foster, Joseph M, et al.
Publicado: (2015)

Preoperative radiotherapy combined with 5 days per week capecitabine chemotherapy in locally advanced rectal cancer
por: Craven, I, et al.
Publicado: (2007)

Effectiveness and safety of capecitabine, irinotecan and panitumumab in advanced colorectal cancer
por: Yip, Pui Lam, et al.
Publicado: (2023)

Biweekly cetuximab in combination with capecitabine and oxaliplatin (XELOX) or irinotecan (XELIRI) in the first-line and second-line treatment of patients with RAS wild-type metastatic colorectal cancer
por: Zekri, Jamal, et al.
Publicado: (2022)

SAT219 Severe Isolated Hypocalcemia With Cetuximab & Irinotecan Chemotherapy
por: Thomas, Melbin, et al.
Publicado: (2023)

Long Term Real-World Outcomes of Trifluridine/Tipiracil in Metastatic Colorectal Cancer—A Single UK Centre Experience
por: Tong, Daniel, et al.
Publicado: (2021)

Impact of the putative cancer stem cell markers and growth factor receptor expression on the sensitivity of ovarian cancer cells to treatment with various forms of small molecule tyrosine kinase inhibitors and cytotoxic drugs
por: Puvanenthiran, Soozana, et al.
Publicado: (2016)

A phase I/II study of irinotecan when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: a Colorectal Clinical Oncology Group Study
por: Glynne-Jones, R, et al.
Publicado: (2007)

Comparison of two preoperative chemoradiotherapy regimens for locally advanced rectal cancer: capecitabine alone versus capecitabine plus irinotecan
por: Lee, Sung Uk, et al.
Publicado: (2013)

Capecitabine and mitomycin C in patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan
por: Alliot, C
Publicado: (2006)

NEOSCOPE: A randomised phase II study of induction chemotherapy followed by oxaliplatin/capecitabine or carboplatin/paclitaxel based pre-operative chemoradiation for resectable oesophageal adenocarcinoma
por: Mukherjee, Somnath, et al.
Publicado: (2017)

Differential and longitudinal immune gene patterns associated with reprogrammed microenvironment and viral mimicry in response to neoadjuvant radiotherapy in rectal cancer
por: Wilkins, Anna, et al.
Publicado: (2021)

Phase II study of capecitabine and irinotecan combination chemotherapy in patients with advanced gastric cancer
por: Baek, J H, et al.
Publicado: (2006)

Reply: Capecitabine and mitomycin C in patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan
por: Chong, G, et al.
Publicado: (2006)

Phase II study of weekly irinotecan and capecitabine treatment in metastatic colorectal cancer patients
por: Li, Wenhua, et al.
Publicado: (2014)

Gemcitabine, Docetaxel, Capecitabine, Cisplatin, Irinotecan as First-line Treatment for Metastatic Pancreatic Cancer
por: Wilbur, H. Catherine, et al.
Publicado: (2023)

Acquired resistance to anti-EGFR mAb ICR62 in cancer cells is accompanied by an increased EGFR expression, HER-2/HER-3 signalling and sensitivity to pan HER blockers
por: Khelwatty, Said A, et al.
Publicado: (2015)

NEOSCOPE: a randomised Phase II study of induction chemotherapy followed by either oxaliplatin/capecitabine or paclitaxel/carboplatin based chemoradiation as pre-operative regimen for resectable oesophageal adenocarcinoma
por: Mukherjee, Somnath, et al.
Publicado: (2015)

Randomized Phase II Trial of Irinotecan/Docetaxel or Irinotecan/Docetaxel Plus Cetuximab for Metastatic Pancreatic Cancer: An Eastern Cooperative Oncology Group Study
por: Burtness, Barbara, et al.
Publicado: (2016)

Extended RAS Analysis of the Phase III EPIC Trial: Irinotecan + Cetuximab Versus Irinotecan as Second‐Line Treatment for Patients with Metastatic Colorectal Cancer
por: Sobrero, Alberto, et al.
Publicado: (2020)

A phase I and II study of 2-weekly irinotecan with capecitabine in advanced gastroesophageal adenocarcinoma
por: Burge, M E, et al.
Publicado: (2006)

Bevacizumab in combination with biweekly capecitabine and irinotecan, as first-line treatment for patients with metastatic colorectal cancer
por: García-Alfonso, P, et al.
Publicado: (2010)

Capecitabine and irinotecan with bevacizumab 2-weekly for metastatic colorectal cancer: the phase II AVAXIRI study
por: Garcia-Alfonso, Pilar, et al.
Publicado: (2015)

Combination effects of capecitabine, irinotecan and 17-AAG on colorectal cancer cell line (HT-29)
por: Zeynali-Moghaddam, Shima, et al.
Publicado: (2022)

Oxaliplatin/capecitabine or carboplatin/paclitaxel-based preoperative chemoradiation for resectable oesophageal adenocarcinoma (NeoSCOPE): Long-term results of a randomised controlled trial
por: Mukherjee, Somnath, et al.
Publicado: (2021)

Co-Expression of HER Family Members in Patients with Dukes’ C and D Colon Cancer and Their Impacts on Patient Prognosis and Survival
por: Khelwatty, Said Abdullah, et al.
Publicado: (2014)

Co-expression and prognostic significance of putative CSC markers CD44, CD133, wild-type EGFR and EGFRvIII in metastatic colorectal cancer
por: Khelwatty, Said Abdullah, et al.
Publicado: (2019)

Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan
por: Chong, G, et al.
Publicado: (2005)

Radiotherapy for rectal cancer: Short course versus long course – When and how
por: Sebag-Montefiore, David
Publicado: (2013)

Cost-effectiveness Analysis of Fluorouracil, Leucovorin, and Irinotecan versus Epirubicin, Cisplatin, and Capecitabine in Patients with Advanced Gastric Adenocarcinoma
por: Wen, Feng, et al.
Publicado: (2016)

Phase 1 Study of ABT‐751 in Combination With CAPIRI (Capecitabine and Irinotecan) and Bevacizumab in Patients With Advanced Colorectal Cancer
por: Rudek, Michelle A., et al.
Publicado: (2016)

Bevacizumab plus capecitabine as later-line treatment for patients with metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines
por: Bang, Yeong Hak, et al.
Publicado: (2021)

A phase II study of neoadjuvant capecitabine, oxaliplatin, and irinotecan (XELOXIRI) in patients with locally advanced rectal cancer
por: Matsuda, Chu, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_hgrqm72n0id96aljesmmts299o